Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

470.2

$million

Invested

103

innovative

Projects

13

different

Countries

12

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2023

Annual Report

Accelerating the Global Response to Antimicrobial Resistance

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
Wellcome
UK Government
BARDA
NIAID
Novo Nordisk Foundation
The Public Health Agency of Canada

Alliance Partners

Bill and Melinda Gates Foundation

Events

Events

09.05.24

 

World AMR Congress 2024

09.17.24

 

ESCMID/ASM 2024

10.16.24

 

IDWeek 2024

CARB-X News

  • 06.13.2024  |  Carb-X funds Fuse Diagnostics to develop innovative, instrument-free diagnostic for chlamydia and drug-resistant gonorrhea full release

  • 05.21.2024  |  CARB-X funds University of Maryland to develop a vaccine to prevent neonatal sepsis full release

  • 04.30.2024  |  CARB-X 2023 Annual Report released today full release

See All News

In The News

  • 04.17.2024  |  As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene full story

  • 03.08.2024  |  Professor Kevin Outterson speaks on antimicrobial resistance full story

  • 03.06.2024  |  CARB-X Funds 100th Project—a Milestone for BU-Based Nonprofit Leading Antimicrobial-Resistance Fightback full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.